TGFBI Human; Transforming Growth Factor Beta Induced Human Recombinant; Transforming growth factor-beta-induced protein ig-h3; Beta ig-h3; Kerato-epithelin; RGD-containing collagen-associated protein; RGD-CAP; TGFBI; BIGH3; CSD; CDB1; CDG2; CSD1; CSD2; CSD3; EBMD; LCD1; CDGG1

For Research Use Only. Not for use in diagnostic procedures.

E Coli

Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

The TGFBI recombinant Human is formulated 20mM Tris pH-8.
Sterile filtered liquid formulation.

Transforming Growth Factor Beta Induced protein Recombinant Human although stable at 4 degree C for 30 days, should be stored below -20 degree C for periods greater than 30 days. Please avoid Freeze/Thaw cycles.

Small volumes of TGFBI recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Description: TGFBI Human Recombinant (fourth FAS domain) produced in E Coli is a single, non-glycosylated, polypeptide containing 135 amino acids (502-636) and having a molecular mass of 14.5 kDa. The TGFBI recombinant Human protein is purified by proprietary chromatographic techniques.

Introduction: Transforming Growth Factor Beta Induced protein also known as TGFBI is an extracellular matrix protein induced by transforming growth factor (TGF)-beta 1. TGFBI protein is involved in cell growth, cell differentiation, wound healing and cell adhesion. In addition, some missense mutations of TGFBI were identified in families affected with human autosomal dominant corneal dystrophies. TGFBI gene encodes for a 683 amino-acid protein containing an RGD motif and four internal repeated domains which have highly conserved sequences founded in several species (Fasciclin domain).

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins; Transforming Growth Factor Beta Induced

74,681 Da

transforming growth factor, beta-induced, 68kDa

transforming growth factor-beta-induced protein ig-h3; RGD-CAP; RGD-containing collagen-associated protein; beta ig-h3; kerato-epithelin; transforming growth factor, beta-induced, 68kD

Transforming growth factor-beta-induced protein ig-h3

BIGH3; Beta ig-h3; RGD-CAP??[Similar Products]

BGH3_HUMAN

This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The RGD motif is found in many extracellular matrix proteins modulating cell adhesion and serves as a ligand recognition sequence for several integrins. This protein plays a role in cell-collagen interactions and may be involved in endochondrial bone formation in cartilage. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion. Mutations in this gene are associated with multiple types of corneal dystrophy. [provided by RefSeq, Jul 2008]

betaIG-H3: Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation. By TGFB1. Highly expressed in the corneal epithelium.

Protein type: Secreted, signal peptide; Cell adhesion; Extracellular matrix; Secreted

Chromosomal Location of Human Ortholog: 5q31

Cellular Component: extracellular matrix; extracellular space; proteinaceous extracellular matrix; plasma membrane; extracellular region; basement membrane; trans-Golgi network

Molecular Function: collagen binding; integrin binding; protein binding; extracellular matrix binding

Biological Process: cell proliferation; extracellular matrix organization and biogenesis; visual perception; response to stimulus; chondrocyte differentiation; negative regulation of cell adhesion; angiogenesis; cell adhesion

Disease: Corneal Dystrophy, Epithelial Basement Membrane; Corneal Dystrophy, Lattice Type Iiia; Corneal Dystrophy, Avellino Type; Corneal Dystrophy Of Bowman Layer, Type Ii; Corneal Dystrophy, Lattice Type I; Corneal Dystrophy Of Bowman Layer, Type I; Corneal Dystrophy, Groenouw Type I

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.